

Matthias G Edinger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8564569/publications.pdf>

Version: 2024-02-01

101
papers

12,756
citations

81743

39
h-index

46693

89
g-index

102
all docs

102
docs citations

102
times ranked

20062
citing authors

#	ARTICLE	IF	CITATIONS
1	Prolonged Suppression of Butyrate-Producing Bacteria Is Associated With Acute Gastrointestinal Graft-vs-Host Disease and Transplantation-Related Mortality After Allogeneic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2022, 74, 614-621.	2.9	20
2	Low Intestinal IL22 Associates With Increased Transplant-Related Mortality After Allogeneic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2022, 13, 857400.	2.2	5
3	Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated <i>versus</i> Tâ€cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 193, 592-601.	1.2	17
4	Discovery of widespread transcription initiation at microsatellites predictable by sequence-based deep neural network. <i>Nature Communications</i> , 2021, 12, 3297.	5.8	11
5	Primary vaccination in adult patients after allogeneic hematopoietic stem cell transplantation â€“ A single center retrospective efficacy analysis. <i>Vaccine</i> , 2021, 39, 4742-4750.	1.7	7
6	Abatacept as salvage therapy in chronic graft-versus-host diseaseâ€”a retrospective analysis. <i>Annals of Hematology</i> , 2021, 100, 779-787.	0.8	10
7	GPR Expression in Intestinal Biopsies From SCT Patients Is Upregulated in GvHD and Is Suppressed by Broad-Spectrum Antibiotics. <i>Frontiers in Immunology</i> , 2021, 12, 753287.	2.2	6
8	Retrospective Comparison between 12-Gray and 8-Gray Total Body Irradiation (TBI) before Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Lymphoblastic Leukemia in First Complete Remission. <i>Blood</i> , 2021, 138, 1783-1783.	0.6	4
9	Efficient treatment of murine acute GvHD by in vitro expanded donor regulatory T cells. <i>Leukemia</i> , 2020, 34, 895-908.	3.3	34
10	Evaluation of the Cost of Survivorship Care After Allogeneic Hematopoietic Stem Cell Transplantationâ€”An Analysis of 2 German Transplantation Centers. <i>Frontiers in Public Health</i> , 2020, 8, 572470.	1.3	4
11	Cyclophosphamide for salvage therapy of chronic graft-versus-host disease: a retrospective analysis. <i>Annals of Hematology</i> , 2020, 99, 2181-2190.	0.8	7
12	International Regensburg Center for Interventional Immunology (RCI) symposium on â€œSynthetic immunology and environment-adapted redirection of T cellsâ€; 17â€”18 July, 2019, Regensburg, Germany. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 677-682.	2.0	0
13	IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. <i>Annals of Hematology</i> , 2020, 99, 847-853.	0.8	21
14	Mechanisms governing the pioneering and redistribution capabilities of the non-classical pioneer PU.1. <i>Nature Communications</i> , 2020, 11, 402.	5.8	76
15	Treosulfan conditioning for allogeneic transplantation in multiple myeloma â€” improved overall survival in first line haematopoietic stem cell transplantation â€” a large retrospective study by the Chronic Malignancies Working Party of the EBMT. <i>British Journal of Haematology</i> , 2020, 189, e213-e217.	1.2	10
16	A Prospective Controlled Trial to Evaluate Safety and Efficacy of in vitro Expanded Recipient Regulatory T Cell Therapy and Tocilizumab Together With Donor Bone Marrow Infusion in HLA-Mismatched Living Donor Kidney Transplant Recipients (Trex001). <i>Frontiers in Medicine</i> , 2020, 7, 634260.	1.2	10
17	Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. <i>Lancet, The</i> , 2020, 395, 1627-1639.	6.3	266
18	Long-term follow-up of rituximab in treatment of chronic graft-versus-host diseaseâ€”single center experience. <i>Annals of Hematology</i> , 2019, 98, 2399-2405.	0.8	5

#	ARTICLE	IF	CITATIONS
19	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). European Journal of Immunology, 2019, 49, 1457-1973.	1.6	766
20	Thymus-Derived CD4+CD25+ FOXP3+ Regulatory T Cells in GVHD. , 2019, , 211-229.		0
21	Haploidentical CD3 or $\hat{I}\pm/\hat{I}^2$ T-cell depleted HSCT in advanced stage sickle cell disease. Bone Marrow Transplantation, 2019, 54, 1859-1867.	1.3	39
22	Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. Haematologica, 2019, 104, 955-962.	1.7	18
23	Stem Cell Transplantation in Advanced Stage Sickle Cell Disease with Haploidentical T-Cell Depleted PBSC Yields Comparable Outcomes to Matched Sibling Donor Bone Marrow: Results of a Pilot Study. Blood, 2018, 132, 3455-3455.	0.6	2
24	Assessment of Calcineurin Inhibitor-Associated Neurotoxicity in Patients with Sickle Cell Disease Receiving a Matched Sibling Donor or T-Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation. Blood, 2018, 132, 2088-2088.	0.6	1
25	Profiling T Cell Receptor Repertoires in Phase I/II Clinical Trials of Donor Treg Infusion for the Treatment of Chronic Graft-Versus-Host Disease. Blood, 2018, 132, 4563-4563.	0.6	0
26	Altered immune reconstitution of B and T cells precedes the onset of clinical symptoms of chronic graft-versus-host disease and is influenced by the type of onset. Annals of Hematology, 2017, 96, 299-310.	0.8	17
27	FANTOM5 CAGE profiles of human and mouse samples. Scientific Data, 2017, 4, 170112.	2.4	195
28	Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia, 2017, 31, 2398-2406.	3.3	232
29	Relation between Acute GVHD and NK Cell Subset Reconstitution Following Allogeneic Stem Cell Transplantation. Frontiers in Immunology, 2016, 7, 595.	2.2	36
30	High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematology, the, 2016, 3, e388-e397.	2.2	128
31	Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia, 2016, 30, 562-569.	3.3	42
32	Driving allotolerance: CAR-expressing Tregs for tolerance induction in organ and stem cell transplantation. Journal of Clinical Investigation, 2016, 126, 1248-1250.	3.9	11
33	Identification and characterization of the specific murine NK cell subset supporting graft-versus-leukemia- and reducing graft-versus-host-effects. Oncoimmunology, 2015, 4, e981483.	2.1	38
34	Basophils inhibit proliferation of $\langle \text{scp} \rangle \text{CD} \langle / \text{scp} \rangle 4 \langle \text{sup} \rangle + \langle / \text{sup} \rangle \langle \text{scp} \rangle \text{T} \langle / \text{scp} \rangle$ cells in autologous and allogeneic mixed lymphocyte reactions and limit disease activity in a murine model of graft versus host disease. Immunology, 2015, 145, 202-212.	2.0	7
35	CD19+CD21 ^{low} B Cells and CD4+CD45RA+CD31+ T Cells Correlate with First Diagnosis of Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2015, 21, 250-258.	2.0	47
36	Total nodal irradiation in patients with severe treatment-refractory chronic graft-versus-host disease after allogeneic stem cell transplantation: Response rates and immunomodulatory effects. Radiotherapy and Oncology, 2015, 116, 287-293.	0.3	6

#	ARTICLE	IF	CITATIONS
37	Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. <i>Annals of Hematology</i> , 2015, 94, 2015-2024.	0.8	67
38	Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA. <i>Blood</i> , 2015, 126, 1581-1581.	0.6	0
39	Langerhans cells promote early germinal center formation in response to <i>Leishmania</i> -derived cutaneous antigens. <i>European Journal of Immunology</i> , 2014, 44, 2955-2967.	1.6	23
40	Physiologic TLR9-CpG-DNA Interaction Is Essential for the Homeostasis of the Intestinal Immune System. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 136-143.	0.9	15
41	A promoter-level mammalian expression atlas. <i>Nature</i> , 2014, 507, 462-470.	13.7	1,838
42	The enhancer and promoter landscape of human regulatory and conventional T-cell subpopulations. <i>Blood</i> , 2014, 123, e68-e78.	0.6	77
43	Metagenomic Analysis of the Stool Microbiome in Patients Receiving Allogeneic Stem Cell Transplantation: Loss of Diversity Is Associated with Use of Systemic Antibiotics and More Pronounced in Gastrointestinal Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 640-645.	2.0	444
44	Transcription and enhancer profiling in human monocyte subsets. <i>Blood</i> , 2014, 123, e90-e99.	0.6	157
45	The Impact of a Tumor Diagnosis on Patients' Attitudes toward Advance Directives. <i>Oncology</i> , 2014, 87, 246-256.	0.9	16
46	Extracorporeal photopheresis in 62 patients with acute and chronic GVHD: Results of treatment with the COBE Spectra System. <i>Bone Marrow Transplantation</i> , 2013, 48, 439-445.	1.3	42
47	TLR5 stop codon polymorphism is associated with invasive aspergillosis after allogeneic stem cell transplantation. <i>Medical Mycology</i> , 2013, 51, 818-825.	0.3	42
48	Current Practice in Diagnosis and Treatment of Acute Graft-versus-Host Disease: Results from a Survey among German-Austrian-Swiss Hematopoietic Stem Cell Transplant Centers. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 767-776.	2.0	49
49	Natural CD4+CD25+FOXP3+ regulatory T cells in graft-versus-host disease. , 2013, , 245-270.		0
50	A new approach for eradication of residual lymphoma cells by host nonreactive anti-“third-party central memory CD8 T cells. <i>Blood</i> , 2013, 121, 3033-3040.	0.6	3
51	Regulatory T Cells Preserve Anti-Viral Immunity While Preventing Lethal Graft-Versus-Host Disease. <i>Blood</i> , 2013, 122, 5432-5432.	0.6	0
52	Whole-Body UVB Irradiation during Allogeneic Hematopoietic Cell Transplantation Is Safe and Decreases Acute Graft-versus-Host Disease. <i>Journal of Investigative Dermatology</i> , 2012, 132, 179-187.	0.3	29
53	Dominant Th2 Differentiation of Human Regulatory T Cells upon Loss of FOXP3 Expression. <i>Journal of Immunology</i> , 2012, 188, 1275-1282.	0.4	60
54	Vaccination against pandemic H1N1 (2009) in patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. <i>Infection</i> , 2012, 40, 153-161.	2.3	22

#	ARTICLE	IF	CITATIONS
55	The lack of memory B cells including T cell independent IgM+ α CD19 ⁺ memory B cells in chronic graft-versus host disease is associated with susceptibility to infection. <i>Transplant International</i> , 2012, 25, 87-96.	0.8	22
56	Novel Serial Positive Enrichment Technology Enables Clinical Multiparameter Cell Sorting. <i>PLoS ONE</i> , 2012, 7, e35798.	1.1	54
57	Regulatory T cells in stem cell transplantation: strategies and first clinical experiences. <i>Current Opinion in Immunology</i> , 2011, 23, 679-684.	2.4	153
58	Tryptophan catabolism is associated with acute GVHD after human allogeneic stem cell transplantation and indicates activation of indoleamine 2,3-dioxygenase. <i>Blood</i> , 2011, 118, 6971-6974.	0.6	52
59	Epigenetic reprogramming of the <i>RORC</i> locus during in vitro expansion is a distinctive feature of human memory but not naive Treg. <i>European Journal of Immunology</i> , 2011, 41, 1491-1498.	1.6	57
60	Efficient Treatment of Murine Acute Graft-Versus-Host Disease with In Vitro Expanded CD4 ⁺ CD25 ⁺ Regulatory T Cells. <i>Blood</i> , 2011, 118, 2987-2987.	0.6	1
61	Increased Susceptibility to Fungal Infection in Recipients with GVHD Is Not Due to Impaired Pathogen Clearance and Can Be Prevented by Co-Transfer of Donor CD4 ⁺ CD25 ⁺ Regulatory T Cells. <i>Blood</i> , 2011, 118, 822-822.	0.6	0
62	Graft-Versus-Host Disease Impairs Early B Lymphopoiesis in the Bone Marrow. <i>Blood</i> , 2011, 118, 2976-2976.	0.6	7
63	Isolation of intact genomic DNA from FOXP3 ⁺ sorted human regulatory T cells for epigenetic analyses. <i>European Journal of Immunology</i> , 2010, 40, 1510-1512.	1.6	11
64	Polyclonal Expansion of Human CD4 ⁺ CD25 ⁺ Regulatory T Cells. <i>Methods in Molecular Biology</i> , 2010, 677, 15-30.	0.4	26
65	Lineage-specific DNA methylation in T cells correlates with histone methylation and enhancer activity. <i>Genome Research</i> , 2009, 19, 1165-1174.	2.4	206
66	Loss of FOXP3 expression in natural human CD4 ⁺ CD25 ⁺ regulatory T cells upon repetitive <i>in vitro</i> stimulation. <i>European Journal of Immunology</i> , 2009, 39, 1088-1097.	1.6	298
67	Regulatory T cells for the prevention of graft-versus-host disease: Professionals defeat amateurs. <i>European Journal of Immunology</i> , 2009, 39, 2966-2968.	1.6	27
68	Regulatory Mechanisms in Graft-versus-Host Responses. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 2-6.	2.0	21
69	Regulatory T-Cell Suppression of CD8 ⁺ T-Cell-Mediated Graft-Versus-Host Reaction Requires Their Presence During Priming. <i>Transplantation</i> , 2009, 88, 188-197.	0.5	30
70	Pharmaceutical and Cellular Strategies in Prophylaxis and Treatment of Graft-Versus-Host Disease. <i>Current Pharmaceutical Design</i> , 2009, 15, 1974-1997.	0.9	33
71	Recipient NOD2/CARD15 status affects cellular infiltrates in human intestinal graft-versus-host disease. <i>Clinical and Experimental Immunology</i> , 2009, 159, 87-92.	1.1	29
72	Functionally Defined T Cell Subsets in Transplantation Biology and Therapy: Regulatory T Cells and Th2 Cells. <i>Cancer Treatment and Research</i> , 2009, 144, 155-186.	0.2	1

#	ARTICLE	IF	CITATIONS
73	CD4+ CD25+ regulatory T cells approach the clinic. <i>Cytotherapy</i> , 2008, 10, 655-656.	0.3	5
74	Only MHC-Identical Donor CD4+CD25+ Regulatory T Cells Convey Full Protection from Lethal Graft-Versus-Host Disease. <i>Blood</i> , 2008, 112, 3516-3516.	0.6	1
75	Delayed Onset of T Cell-Mediated Xenogeneic Disease in Rag2 ^{~-/~} Î³c ^{~-/~} mice after Co- Transplantation of in Vitro Expanded Human CD4+CD25 ^{high} CD45RA+ Regulatory T Cells. <i>Blood</i> , 2008, 112, 4609-4609.	0.6	3
76	Inhibitory effect of tumor cell-derived lactic acid on human T cells. <i>Blood</i> , 2007, 109, 3812-3819.	0.6	1,361
77	DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3 ⁺ conventional T cells. <i>European Journal of Immunology</i> , 2007, 37, 2378-2389.	1.6	620
78	Loss of FOXP3 Expression and Emergence of Cytokine-Producing Cells after In Vitro Expansion of Human CD4+CD25+CD127 - Regulatory T Cells.. <i>Blood</i> , 2007, 110, 63-63.	0.6	4
79	CD4+CD25+ Regulatory T Cells and Graft-Versus-Host Disease. <i>Seminars in Hematology</i> , 2006, 43, 62-69.	1.8	55
80	Isolation of CD4+CD25+ Regulatory T Cells for Clinical Trials. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 267-274.	2.0	123
81	Only the CD45RA+ subpopulation of CD4+CD25 ^{high} T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. <i>Blood</i> , 2006, 108, 4260-4267.	0.6	372
82	Low-Dose Cyclosporin A Does Not Abrogate the Suppressive Function of In Vitro Expanded Human CD4+CD25+ Regulatory T Cells.. <i>Blood</i> , 2006, 108, 5170-5170.	0.6	0
83	Only Naive CD45RA+CD4+CD25 ^{high} T Cells from Human Peripheral Blood Give Rise to Homogeneous Regulatory T Cell Lines.. <i>Blood</i> , 2006, 108, 3163-3163.	0.6	0
84	Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. <i>Blood</i> , 2005, 105, 2220-2226.	0.6	379
85	Immunomodulation after allogeneic bone marrow transplantation by CD4+CD25+ regulatory T cells. <i>Microbes and Infection</i> , 2005, 7, 1066-1072.	1.0	6
86	Low Levels of Her2/neu Expressed by Ewing's Family Tumor Cell Lines Can Redirect Cytokine-Induced Killer Cells. <i>Clinical Cancer Research</i> , 2005, 11, 4561-4570.	3.2	30
87	A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 181-187.	2.0	194
88	Multi-modality Imaging Identifies Key Times for Annexin V Imaging as an Early Predictor of Therapeutic Outcome. <i>Molecular Imaging</i> , 2004, 3, 153535002004031.	0.7	1
89	Large-scale in vitro expansion of polyclonal human CD4+CD25 ^{high} regulatory T cells. <i>Blood</i> , 2004, 104, 895-903.	0.6	461
90	Immunoregulation in human bone marrow transplantation?. <i>Blood</i> , 2004, 104, 1920-1920.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Multi-modality Imaging Identifies Key Times for Annexin V Imaging as an Early Predictor of Therapeutic Outcome. <i>Molecular Imaging</i> , 2004, 3, 1-8.	0.7	54
92	Isolation of Human CD4+CD25+ T Cells with Regulatory Capacity for Clinical Trials.. <i>Blood</i> , 2004, 104, 2851-2851.	0.6	0
93	Inhibitory Effects of Lactic Acid on Human Antigen-Specific CD8+ T-Cells.. <i>Blood</i> , 2004, 104, 3844-3844.	0.6	0
94	CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. <i>Nature Medicine</i> , 2003, 9, 1144-1150.	15.2	1,174
95	Evaluation of effector cell fate and function by in vivo bioluminescence imaging. <i>Methods</i> , 2003, 31, 172-179.	1.9	75
96	Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. <i>Blood</i> , 2003, 101, 640-648.	0.6	302
97	Donor-type CD4+CD25+ Regulatory T Cells Suppress Lethal Acute Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation. <i>Journal of Experimental Medicine</i> , 2002, 196, 389-399.	4.2	1,012
98	Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice. <i>Journal of Clinical Immunology</i> , 2002, 22, 131-136.	2.0	62
99	Bioluminescence imaging of lymphocyte trafficking in vivo. <i>Experimental Hematology</i> , 2001, 29, 1353-1360.	0.2	146
100	Noninvasive Assessment of Tumor Cell Proliferation in Animal Models. <i>Neoplasia</i> , 1999, 1, 303-310.	2.3	224
101	Lipopeptide-Polyoxyethylene Conjugates as Mitogens and Adjuvants. <i>Immunobiology</i> , 1994, 190, 53-66.	0.8	18